Home/Anodyne Nanotech/Michael Elliott

ME

Michael Elliott

COO

Anodyne Nanotech

Therapeutic Areas

Metabolic Disease Endocrinology Age-related Conditions

Anodyne Nanotech Pipeline

Drug	Indication	Phase
Pipeline not specifically named	Obesity, Sarcopenia, and other metabolic/endocrine conditions	Clinical-stage (phase unspecified)

Leadership Team at Anodyne Nanotech

Co-Founder & CEO

Konstantinos Tzortzakis

Co-Founder & CBO

Hojat Rezaei Nejad, PhD

Co-Founder & CTO

Chirag B. Shah, PhD

VP R&D and Product Development

View full Anodyne Nanotech profile